Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications
The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Various pathologies are characterized by the accumulation of toxic iron in cell compartments. In anemia of chronic disease, iron is withheld by macrophages, leaving extracellular fluids iron-depleted. In Friedreich ataxia, iron levels rise in the mitochondria of excitable cells but decrease in the cytosol. We explored the possibility of using deferiprone, a membrane-permeant iron chelator in clinical use, to capture labile iron accumulated in specific organelles of cardiomyocytes and macrophages and convey it to other locations for physiologic reuse. Deferiprone's capacity for shuttling iron between cellular organelles was assessed with organelle-targeted fluorescent iron sensors in conjunction with time-lapse fluorescence microscopy imaging. Deferiprone facilitated transfer of iron from extracellular media into nuclei and mitochondria, from nuclei to mitochondria, from endosomes to nuclei, and from intracellular compartments to extracellular apotransferrin. Furthermore, it mobilized iron from iron-loaded cells and donated it to preerythroid cells for hemoglobin synthesis, both in the presence and in the absence of transferrin. These unique properties of deferiprone underlie mechanistically its capacity to alleviate iron accumulation in dentate nuclei of Friedreich ataxia patients and to donate tissue-chelated iron to plasma transferrin in thalassemia intermedia patients. Deferiprone's shuttling properties could be exploited clinically for treating diseases involving regional iron accumulation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“clinical symptoms include cardiac hypertrophy [1128] and (pre-)diabetes [1129], consistent with the general thesis described here that all are in part manifestations of iron dysregulation, and in which suitable chelation may be beneficial [1130,1131]”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [1131]
Citations
Cites
Weiss, G., & Goodnough, L. T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041809 · Cited by 3,800
Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation
Ganz, T. (2003) · Blood · doi:10.1182/blood-2003-03-0672 · Cited by 1,544
Iron Transport and Storage Proteins
Aisen, P., & Listowsky, I. (1980) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.49.070180.002041 · Cited by 1,171
Labile iron pool: the main determinant of cellular response to oxidative stress
Kruszewski, M. (2003) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2003.08.004 · Cited by 533
Labile plasma iron in iron overload: redox activity and susceptibility to chelation
Esposito, B. P., Breuer, W., Sirankapracha, P., Pootrakul, P., Hershko, C., & Cabantchik, Z. I. (2003) · Blood · doi:10.1182/blood-2003-03-0807 · Cited by 475
Self-citationCytokine-mediated regulation of iron transport in human monocytic cells
Ludwiczek, S., Aigner, E., Theurl, I., & Weiss, G. (2003) · Blood · doi:10.1182/blood-2002-08-2459 · Cited by 420
Selective iron chelation in Friedreich ataxia: biologic and clinical implications
Boddaert, N., Le Quan Sang, K. H., Rötig, A., Leroy-Willig, A., Gallet, S., Brunelle, F., Sidi, D., Thalabard, J.-C., Munnich, A., & Cabantchik, Z. I. (2007) · Blood · doi:10.1182/blood-2006-12-065433 · Cited by 409
Self-citationNeurodegeneration with brain iron accumulation
(2018) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-63233-3.00019-1 · Cited by 317
Iron trafficking in the mitochondrion: novel pathways revealed by disease
Napier, I., Ponka, P., & Richardson, D. R. (2005) · Blood · doi:10.1182/blood-2004-10-3856 · Cited by 288
Rouault, T. A., & Cooperman, S. (2006) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2006.08.002 · Cited by 280
Research works printed but not linked: 1
- Evans, 1992, The effect of alpha-ketohydroxypyridine chelators on transferrin saturation in vitro and in vivo., Drugs Today (Barc), 28, 19
Cited by
Mitochondrial function as a therapeutic target in heart failure
Brown, D. A., Perry, J. B., Allen, M. E., Sabbah, H. N., Stauffer, B. L., Shaikh, S. R., Cleland, J. G. F., Colucci, W. S., Butler, J., Voors, A. A., et al. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.203 · Cited by 803
Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease
Devos, D., Moreau, C., Devedjian, J. C., Kluza, J., Petrault, M., Laloux, C., Jonneaux, A., Ryckewaert, G., Garçon, G., Rouaix, N., et al. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5593 · Cited by 619
“…in experimental models of PD and in the clinical setting: (i) its ability to rescue iron-overloaded cells by scavenging labile iron (24, 64), especially from mitochondria, the organelles most affected by cell iron accumulation and ensuing labile iron-mediated oxidative damage (3, 24,…”
InfluentialSelf-citationKell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
“As well as the neurodegeneration and measurable iron deposition, clinical symptoms include cardiac hypertrophy [1012] and (pre-)diabetes [1013], consistent with the general thesis described here that all are in part manifestations of iron dysregulation, and in which suitable chelation may be beneficial [1014; 1015] (b…”
BackgroundMartin-Bastida, A., Ward, R. J., Newbould, R., Piccini, P., Sharp, D., Kabba, C., Patel, M. C., Spino, M., Connelly, J., Tricta, F., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-01402-2 · Cited by 379
Kell, D. B. (2010) · Archives of Toxicology · doi:10.1007/s00204-010-0577-x · Cited by 361
“As would be expected, appropriate iron chelation may have therapeutic benefits (Boddaert et al. 2007; Campanella et al. 2009; Goncalves et al. 2008; Kakhlon et al. 2010; Lim et al. 2008; Marmolino and Acquaviva 2009; Santos et al. 2010; Schulz et al. 2009; Sohn et al. 2008).”
Background
Metadata
- Authors
- Sohn, Y.-S., Breuer, W., Munnich, A., & Cabantchik, Z. I.
- Affiliations
- Hebrew University of Jerusalem (IL)
- Clinical Research Unit, Medical Genetic Clinic and Research Unit, Inserm Unite 781, Hôpital Necker-Enfants-Malades and Université Paris V René Descartes, Paris, France
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2008-02-01
- Volume
- 111
- Issue
- 3
- Pages
- 1690-1699
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2055981765
- Cited by
- 167
- References
- 55
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 7 · 2023: 13 · 2022: 5 · 2021: 12 · 2020: 8 · 2019: 9 · 2018: 9 · 2017: 9 · 2016: 9 · 2015: 8 · 2014: 11 · 2013: 11 · 2012: 10
- FWCI
- 6.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Universität Duisburg-Essen
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Keywords
- deferiprone, iron chelation, iron redistribution, labile iron, Friedreich's ataxia, thalassemia intermedia, cardiomyocytes, macrophages, mitochondrial iron, endosomes, apotransferrin, transferrin, anemia of chronic disease, hemoglobin synthesis
- MeSH terms
- Animals, Cell Line, Cell Nucleus, Hemoglobins, Humans, Iron, Iron Chelating Agents, Mitochondria, Protein Binding, Endosomes, Transferrin, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications. https://app.cochat.ai/papers/10.1182/blood-2007-07-102335
- The paper
- Sohn, Y.-S., Breuer, W., Munnich, A., & Cabantchik, Z. I. (2008). Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications. Blood. https://doi.org/10.1182/blood-2007-07-102335
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.